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Background:  It is  unknown  to what  extent  the  human  coronaviruses  (HCoVs)  OC43,  HKU1,  229E and  NL63
infect healthy  children.  Frequencies  of infections  are  only  known  for hospitalized  children.
Objectives:  Comparing  infection  frequencies  in children  who  have  mild  infections  with  frequencies  in
children  needing  hospital  uptake  will  determine  whether  infection  by one  of  the  four  HCoVs  leads  to
more severe  disease.  In addition,  the  sequence  of seroconversions  can  reveal  whether  infection  by  one
HCoV  protects  from  infection  by  other  HCoVs.
Study design:  Two  distinct  study  groups  were  monitored:  healthy  children  and  children  hospitalized  due
to respiratory  infection.  HCoV  natural  infection  rates  in  healthy  children  were  obtained  by serology  in 25
newborns  (followed  0–20  months).  The  frequencies  of  severe  HCoVs  infection  was  determined  by  real
time RT-PCR  among  1471  hospitalized  infants  (<2-years  old)  with  acute  respiratory  tract  disease.
Results:  The  majority  of healthy  children  seroconverted  for  HCoV-OC43  (n =  19) and  HCoV-NL63  (n  =  17),
less  for  HCoV-HKU1  (n =  9)  and  HCoV-229E  (n = 5).  Notably,  HCoV-HKU1  seroconversion  was  absent  after
HCoV-OC43  infection.  Also  HCoV-229E  infection  was  rarely  observed  after  HCoV-NL63  infection  (1 out  of
5). In the  hospital  207  (14%)  out  of 1471  children  were  HCoV  positive.  Again  we  observed  most  infection
by  HCoV-OC43  (n =  85) and  HCoV-NL63  (n  = 60),  followed  by HCoV-HKU1  (n = 47)  and  HCoV-229E  (n  =  15).
Conclusions:  HCoV-NL63  and  HCoV-OC43  infections  occur  frequently  in  early  childhood,  more  often  than
HCoV-HKU1  or HCoV-229E  infections.  HCoV-OC43  and  HCoV-NL63  may  elicit  immunity  that  protects
from  subsequent  HCoV-HKU1  and  HCoV-229E  infection,  respectively,  which  would  explain  why  HCoV-
OC43  and  HCoV-NL63  are  the  most  frequently  infecting  HCoVs.  There  are  no  indications  that  infection
by  one  of the  HCoVs  is  more  pathogenic  than others.. Background
Human coronaviruses (HCoV) NL63, 229E, OC43 and HKU1
re circulating worldwide among the human population and
ause approximately 10% of all upper and lower respiratory tract
llnesses.1–3 In children, infections with HCoV-NL63, HCoV-229E,
CoV-OC43 and HCoV-HKU1 are associated with acute respira-
ory tract illness, pneumonia and croup that eventually may  lead
o hospitalization.4
∗ Corresponding author at: Laboratory of Experimental Virology, University of
msterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.
el.: +31 20 566 75 10; fax: +31 20 691 65 31.
1 Current work address: Institute of Immunobiology, Kantonal Hospital St.Gallen,
t.  Gallen, Switzerland.
386-6532/$ – see front matter. Crown Copyright ©  2011 Published by Elsevier B.V. All ri
oi:10.1016/j.jcv.2011.11.011Crown Copyright ©  2011 Published by Elsevier B.V. All rights reserved.
The severe acute respiratory syndrome (SARS) outbreak in
2002/2003 by a novel coronavirus, followed by the recent iden-
tiﬁcation of HCoV-NL63 (2004) and HCoV-HKU1 (2005) renewed
research interest into HCoV infections and their ability to seriously
affect human health.5–8 Despite the accumulating knowledge on
HCoV prevalence and burden of disease, there are limited stud-
ies on the frequency of infection by all 4 HCoV infections in the
non-hospitalized population during the ﬁrst years of childhood.9–11
2. Objectives
We  established a speciﬁc carboxyl-terminal nucleocapsid (NCt)
protein ELISA system for HCoV-OC43 and HCoV-HKU1 analogous
to that described for HCoV-NL63 and HCoV-229E.12 With this sero-
logical toolset we performed a survey with longitudinal sera from
newborns to identify seroconversion events during the ﬁrst years of
ghts reserved.
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ife. We  compared the serology data with the frequencies of infec-
ion of all 4 HCoVs in hospitalized infants with acute respiratory
ract disease. In addition the chain of seroconversions will reveal
hether immunity to one HCoV may  protect against infection by
ne of the other HCoVs.
. Study design
.1. Patient samples
Two distinct study groups were monitored: healthy children
newborns) and children hospitalized due to respiratory disease.
uman serum specimens from newborns were collected at the
epartment of Medical Microbiology, Academic Medical Center
AMC), Laboratory of Experimental Virology. All children (12 males
nd 13 females) were born to HIV-1-positive mothers, with var-
ous dates of birth (1993, n = 1; 1997, n = 1; 1998, n = 3; 1999,
 = 4; 2000, n = 1; 2001, n = 1; 2002, n = 4; 2003, n = 7; and 2004,
 = 3). In a previous study we compared the average age of
eroconversion in the children born from HIV infected mothers
nd those born from healthy mothers. The mean seroconversion
ge was not different,10 therefore we treated this group of 25
hildren as a representative of the wider population. Serum sam-
les were obtained at birth, age 1 month, 3 months, 12 months,
pproximately 20 months, and for some also at approximately
4 months. Serum samples were stored at −80 ◦C. All newborns
emained HIV-1 RNA negative and were HIV-1 seronegative dur-
ng the follow-up period. Twenty-four of the 25 children were
ever hospitalized during the follow up period. One child was
ospitalized in the ﬁrst month of life due to an inﬂuenza infec-
ion. So none of the 25 children needed hospitalization at the
oment they were infected by the HCoVs. Thirteen of the 25
ewborns were part of a previous survey on HCoV-NL63 and
CoV-229E seroconversion.10 Respiratory samples were not col-
ected. All serum samples were heat-inactivated at 56 ◦C for
0 min.
Respiratory samples from children hospitalized due to res-
iratory infection, were collected and analyzed at the Elisabeth
ospital, Tilburg, Netherlands (n = 168) and The Edinburgh Royal
nﬁrmary (South-east of Scotland) (n = 1303) for routine respi-
atory virus screening.13–15 Samples had been collected during
 consecutive years. Samples in this study were selected from
he complete set based on the following criteria: children
ho were hospitalized with acute respiratory tract illness and
elow the age of 2 years. This provides a selection of chil-
ren of which the HCoV infections are severe enough to require
ospitalization and who encountered their primary HCoV infec-
ion.
.2. Generation and expression of recombinant HCoV
arboxyl-terminal nucleocapsid proteins
In this study the carboxyl-terminal region of the nucle-
capsid (NCt) protein was used as antigen, instead of the
revious used full length N protein.10 This was done to increase
he speciﬁcity of the serological assay. In a previous study
e show that the carboxyl part of the N protein of 229E
nd NL63 elicit speciﬁc antibodies that allow differentiation
etween both species.16 Given the shared structural and func-
ional domain features among coronavirus N proteins we applied
he same approach for HCoV-OC43 and HCoV-HKU1, since cross-
eactivity by the antibodies directed to the full-N of HCoV-OC43
nd HCoV-HKU1 has been reported in human sera.16–18 The
CoV-NL63 and HCoV-229E recombinant NCt proteins were pro-
uced as previously described.12 The generation of the plasmid Virology 53 (2012) 135– 139
for NCt-OC43 and NCt-HKU1 was performed using the same
method. Brieﬂy, for NCt-OC43 the following primer combination
was used 5′ OC43 N5 CT (5′-CACCAGATTAGAGTTGGCCAAAGTG-
3′) and 3′ OC43 Nexp (5′-TTATATTTCTGAGGTGTCTTCAGTATAG-3′),
whereas for NCt-HKU1 the primer combination 5′-HKU1 5N CT (5′-
CACCAAATTAGACTTGGTTAAAAGAGTCCG-3′) and 3′ HKU1 Nexp
(5′-TTAAGCAACAGAGTCTTCTACATAAG-3′) was  used. The gener-
ated pET100 OC43 NCt and pET100 HKU1 NCt plasmids were
sequenced and shown to be 100% identical to the virus reference
sequences of HCoV-HKU1 (Caen1, HM034837) and HCoV-OC43
(VR-759, AY391777), respectively. Subsequent expression and
puriﬁcation of the HCoV recombinant carboxyl-terminal N (NCt)
proteins were performed exactly as described elsewhere.10
The NCt proteins from HCoV-OC43, HCoV-HKU1, like those
from HCoV-NL63 and HCoV-229E, retained their immunogenic-
ity in ELISA (checked with longitudinal sera from adults, or
pooled human intravenous immunoglobulin (IVIg, Sanquin)). We
performed competition experiments to ascertain speciﬁcity: pos-
itive human serum from adults or human IVIG was diluted
(1:200) in PBST containing 1% skim milk, and twofold serial
dilutions (ranging from 0 to 50 g/ml) of NCt protein of HCoV-
NL63, HCoV-229E, HCoV-OC43, or HCoV-HKU1 were added.
The mixtures were brieﬂy homogenized by vortexing prior to
incubation for 1 h at RT. Following the preincubations, the
samples were measured by either NL63- and 229E-ELISA or
OC43- and HKU1-ELISA (so preincubated with the NCt form
the other virus of the same genus). No cross reactivity was
observed.
3.3. Carboxyl-terminal nucleocapsid ELISA
The procedure for the NCt ELISA of HCoV-NL63, HCoV-
OC43, HCoV-HKU1 and HCoV-229E was  performed as previously
described.10,12 Brieﬂy, 96-well ELISA plates (Greiner Bio-one) were
coated overnight at 4 ◦C with 3 g/ml of expressed recombi-
nant NCt protein. Non-speciﬁc binding sites were blocked with
phosphate-buffered saline-0.1% Tween 20 (PBST) supplemented
with 5% skim milk (Fluka) for 1 h at room temperature (RT).
Longitudinal serum samples were diluted 1:200 in PBST con-
taining 1% skim milk and incubated in the plate for 2 h at RT.
After a washing, alkaline phosphatase-conjugated anti-human
immunoglobulin G Fc-tail antibody (Jackson Immunoresearch)
diluted (1:1500) in 1% skim milk–PBST was added. Following
1 h at RT, the plates were washed and signal was  developed
with 50 l of Lumi-Phos Plus (Lumigen). Measurements were
done with a Glomax 96 plate luminometer (Promega). All sera
were tested in duplicate. Seroconversion was deﬁned as a sig-
nal increase of >2.5 compared to that of the preceding time
point.
3.4. Statistical analysis
Calculations were performed using the Prism software ver-
sion 5 (Graphpad). Comparison of longitudinal results from
the cumulative incidence of HCoV-OC43, HCoV-HKU1, HCoV-
NL63 and HCoV-229E seropositive time points was done
with the Kaplan–Meier survival analysis, statistical signiﬁ-
cance was tested with the log-rank (Mantel–Cox) test. The
time point of seroconversion was  calculated by taking the
midpoint between the last seronegative and the ﬁrst seropos-
itive time point. Comparison of the mean prevalence for
HCoV-OC43, HCoV-HKU1, HCoV-NL63 and HCoV-229E infec-
tions among children under the age of 2 years was done
with one-way ANOVA, using the Turkey’s multiple comparison
test.
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Fig. 1. Frequency of infection by the four HCoVs in children. (A) Healthy children:
seroconversion for HCoV-OC43, HCoV-NL63, HCoV-HKU1, HCoV-229E during the
complete follow up period. The Kaplan–Meier survival analysis was  performed on
the  cumulative incidence of the percentage of seronegative individuals (y-axis)
against time (in months; x-axis). Seroconversion to HCoV-NL63 is presented as a
blue line, HCoV-OC43 as a green line, HCoV-229E as a black line and HCoV-HKU1 as
a  red line. (B) Hospitalized children: percentage of coronavirus HCoV-229E, HCoV-
HKU1, HCoV-NL63, and HCoV-OC43 positive patients by age group as determined
by  viral RNA diagnostics. HCoV-NL63, HCoV-OC43, HCoV-229E and HCoV-HKU1 are
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sresented as a blue, green, black and red bar, respectively. (For interpretation of the
eferences to colour in this ﬁgure legend, the reader is referred to the web version
f  the article.)
. Results
.1. Seroconversion during childhood
In this serological survey we measured the antibody levels
owards all four HCoVs in sera collected from 25 newborns who
ere followed until an average of 20 months of age. During this
eriod none of the children were hospitalized due to an HCoV infec-
ion. At birth we observed high levels of antibodies directed to all
our HCoVs that decreased to low detectable levels within a few
onths. This suggests that all newborns carry maternal antibod-
es directed to all four HCoVs. In one newborn (Subject 1) we did
ot observe any seroconversion for the HCoVs during 19 months
ollow up (Table 1). For 5 newborns a single seroconversion was
etected to one of the four HCoVs, whereas for the remaining
ewborns we observed sequential or simultaneous seroconversion
vents. In total, we recorded 17 events of seroconversion towards
CoV-NL63, 19 for HCoV-OC43, 5 for HCoV-229E and 9 towards
CoV-HKU1 (Table 1). No correlation was found between the anti-
ody levels of some of the mothers before and after giving birth and
he seroconversion outcome of their children (data not shown).
To determine whether there is variability in seroconversion
ates for the different HCoV infections we used the cumulative inci-
ence of seroconversion for each virus (Fig. 1A), using the mid-time
oint of each event (Table 1). Statistical analyses (Log-rank, Mantel
ox test) revealed that there are signiﬁcant differences in the fre-
uencies of the four HCoVs. HCoV-OC43 seroconversions occurred
igniﬁcantly more frequently than HCoV-HKU1 (p = 0.0095) and Virology 53 (2012) 135– 139 137
HCoV-229E infections (p ≤ 0.0001), but not HCoV-NL63 infec-
tions (p = 0.1773). For HCoV-NL63 the frequency of seroconversion
was signiﬁcantly higher compared with HCoV-229E (p = 0.0015).
No signiﬁcant difference in seroconversion rates between alpha-
(NL63 and 229E) or betacoronavirus (OC43 and HKU1) was  found
(p = 0.1529).
4.2. Infection frequencies versus disease severity
Our antibody data showed that seroconversion to HCoV-OC43
and HCoV-NL63 occurs most frequently. These seroconversion
frequencies can be compared with the frequencies with which
these viruses are found in hospitalized children – children of the
same age group that appear with respiratory symptoms so severe
that hospitalization was  needed frequently. This study covered 5
consecutive years, and children were included at two locations:
The Netherlands and South-east of Scotland. Between December
2006 and February 2011 a total of 207 (14%) out of 1471 chil-
dren were HCoV infected. HCoV-OC43 (n = 85) was  most frequently
detected, followed by HCoV-NL63 (n = 60), HCoV-HKU1 (n = 47) and
HCoV-229E (n = 15) (Fig. 1B). The frequency of HCoV-229E infec-
tion was signiﬁcantly lower compared to HCoV-NL63 (p ≤ 0.05)
and HCoV-OC43 (p ≤ 0.001). The frequency of HCoV-HKU1 infec-
tion was signiﬁcantly lower compared to HCoV-OC43 (p ≤ 0.05).
Thus, in hospitalized children under the age of 2 years, HCoV-OC43
and HCoV-NL63 were the most common coronaviruses detected,
similar to the higher rates of seroconversion events observed for
these two  viruses.
4.3. Sequence of seroconversions
HCoV-NL63 and HCoV-229E belong to the alphacoronaviruses,
whereas HCoV-OC43 and HCoV-HKU1 are members of the
betacoronaviruses. These groups were originally designed on sero-
logical reactivity, suggesting that antibodies could cross-react with
the other virus from the same group (we were aware of poten-
tial cross reactivity and carefully designed the partial NCt protein
ELISA to best speciﬁcity, see Section 3). Antibodies directed to the
Spike protein have the potential to be neutralizing, and in case these
antibodies cross-react, seroconversion towards one HCoV might
protect against infection by the other virus from the same group.
Inspection of the NL63/229E seroconversion dates shows that
child 7 seroconverted for HCoV-NL63 6 months after HCoV-229E
(December 2004 versus June 2004), suggesting that an HCoV-
229E infection did not protect from HCoV-NL63 infection. Further
inspection showed that in none of the HCoV-229E seroconver-
sions a recent infection by HCoV-NL63 was noted (≤1 year before
HCoV-229E infection) also pointing towards HCoV-NL63 eliciting
protective immunity for HCoV-229E infection. Strikingly, exactly
the same pattern is observed for OC43/HKU1. HCoV-HKU1 sero-
conversions are only observed prior to HCoV-OC43 seroconversion,
telling that also for these two  viruses an infection by HCoV-OC43
elicits immunity that is protective towards an HCoV-HKU1 infec-
tion. This is not vice versa, child 6, 7, 10, and 21 seroconvert for
HCoV-OC43 while they had been infected previously by HCoV-
HKU1, suggesting that an infection with HCoV-HKU1 does not
protect against an HCoV-OC43 infection.
5. Discussion
This is the ﬁrst study on the seroconversion frequencies of all
four HCoVs. In healthy children high frequency of seroconversion
towards HCoV-OC43 and HCoV-NL63 were detected, and to a lesser
extent seroconversion to HCoV-HKU1 and HCoV-229E. Serosurveil-
lance of otherwise healthy individuals subverts bias for analyses of
138 R. Dijkman et al. / Journal of Clinical Virology 53 (2012) 135– 139
Table 1
Mid-time points of seroconversion.
Subject Follow-up period HCoV-NL63 HCoV-229E HCoV-OC43 HCoV-HKU1
Start End Duration (months) Agea Dateb Agea Dateb Agea Dateb Agea Dateb
1 Sept-03 Mar-05 18.9
2 Oct-02 Jul-04 20.9 15.5 Jan-04
3 Apr-04 Mar-06 24.0 21.4 Jan-06 7.3 Nov-04
4 Jul-03 Mar-05 20.6 1.8 Sept-03
5  Jul-02 Dec-04 28.9 13.0 Aug-03
6  Jan-04 Feb-06 25.1 9.0 Oct-04 4.3 May-04
7  Feb-03 Aug-05 21.6 21.6 Dec-04 16.0 Jun-04 21.6 Dec-04 8.7 Oct-03
8 Aug-03 May-05 21.2 17.3 Jan-05 7.4 Mar-04
9 Oct-02 Apr-04 18.6 17.3 Mar-04 9.0 Jul-03
10 Jun-02 Jun-04 23.9 19.4 Jan-04 8.5 Feb-03 1.6 Aug-02
11  Oct-03 May-05 18.8 16.8 Mar-05 9.0 Jul-04
12  Aug-03 Mar-05 18.1 8.9 May-04
13  Sept-03 May-05 19.4 8.6 Jan-04 16.8 Feb-05 16.8 Feb-05
14  Jul-99 Feb-01 19.4 13.0 Aug-00 17.8 Dec-00
15 Nov-00 Jul-02 19.3 2.5 Feb-01
16  Jul-93 Feb-95 19.5 7.4 Feb-94 15.7 Oct-95
17 Dec-97 Jul-99 18.8 14.4 Feb-99 2.6 Mar-98
18  Aug-98 Feb-00 17.8 7.2 Feb-99 7.2 Feb-99
19 Aug-98 Jun-00 22.2 16.1 Dec-99 20.6 May-00
20  Jun-04 Jan-06 19.1 8.2 Feb-05 8.2 Feb-05
21  Aug-99 Apr-01 19.6 16.0 Jan01 16.0 Jan-01 7.3 Apr-00
22  Aug-98 Jul-00 22.4 14.5 Oct-99 14.5 Oct-99 14.5 Oct-99 14.5 Oct-99
23  Dec-99 Sept-01 21.1 1.51 Feb-00 7.5 Aug-00
24 Dec-99 Sept-01 20.4 1.8 Feb-00 15.7 May-01
25  Jan-01 Aug-02 19.1 1.8 Mar-01 9.1 Oct-01
a Age of seroconversion in months.
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atients with higher severity of symptoms as is an inevitable con-
equence of hospital based studies, thus providing a much clearer
epresentation of virus epidemiology in the community. These data
rovide the opportunity to compare the natural infection frequency
f each HCoV with the frequency with which these viruses are found
n hospitalized children with acute respiratory infections within a
ommunity, something that has not been achieved previously. We
nvestigated children who were hospitalized with acute respira-
ory tract illness, below the age of 2 years. This provides a selection
f children with severe HCoV infections requiring hospitalization.
revalence data in these hospital children and the serology in the
ealthy children are in complete accordance, revealing that there
re no indications that any of the four HCoVs causes signiﬁcantly
ore hospitalization than another.
The characteristic frequency of infection, in the order HCoV-
C43 ≥ HCoV-NL63 > HCoV-HKU1 ≥ HCoV-229E, observed via
eroconversion but also by direct detection of the virus in hospital-
zed children over multiple years is in contrast with some previous
tudies. Some studies addressed the frequency of HCoV infec-
ion during childhood and suggested that HCoV-NL63 infections
ere associated with more hospitalization compared to HCoV-
C43.3,19,20 In the majority of the abovementioned studies only 1
ear was sampled and for HCoVs a large year-to-year periodicity is
nown.14,21,22 The signiﬁcant differences of seroconversion rates
etween the coronaviruses observed here cannot be attributed to
ariable circulating frequencies as samples were collected over
ultiple years.
There has never been a clear explanation for the higher fre-
uency of infection for HCoV-OC43 and HCoV-NL63 compared to
CoV-HKU1 and HCoV-229E among children. We  hypothesize that
n infection by HCoV-NL63 elicits neutralizing antibodies directed
o the NL63-Spike protein that might also protect, or partially pro-
ect, against an HCoV-229E infection, whereas this relationship
ay  not be reciprocated, thus providing a greater likelihood of
CoV-NL63 infection than HCoV-229E. The same can count for
CoV-OC43 for which neutralizing antibodies may  protect againstHCoV-HKU1 infection. The seroconversion data we  show here sup-
port our hypothesis, yet conﬁrmation with in vitro neutralization
studies is needed.
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